New Study Validates Cellular Bone Allograft Technology

In a study in laboratory rats that had defects in their femurs (upper leg bone) showed new bone formation after they were treated with adipose-derived mesenchymal stromal cells that had been seeded on demineralized bone matrix and implanted.  Implanted stem cells were detected for up to 84 days in areas of new formation and had differentiated within the bony repair tissue.

According to AlloSource, the procedures used similar technology to the company’s AlloStem Cellular Bone Allograft process.

Surgical oncologist Nicole Ehrhart of Colorado State University presented these data at the State of Spine Surgery annual symposium and at the Korean American Spine Society meeting.

AlloStem is partially demineralized allograft bone combined with adipose-derived mesenchymal stem cells.  AlloStem is suitable for general bone grafting applications, and is similar to autograft bone because it provides the three key properties necessary for bone formation: osteoconduction, osteoinduction and osteogenesis.

Ehrhart’s study has been accepted for publication in Journal of Biomaterials and Tissue Engineering.

AlloSource provides 200 types of precise cartilage, cellular, bone, skin and soft-tissue allografts.